Aujourd'hui, on parle de la vitamine D et le risque du cancer:
- 6 études avec un nombre total de 5984 patients ont été identifiées.
- Au seuil de 23.3 nmol / L, pour un incrément de 10 nmol / L, 20 nmol / L ou 25 nmol / L dans les niveaux circulants de 25-OH-D, le risque de mortalité globale du cancer du sein a diminué de 6%, 12 % et 14%, respectivement.
- Les résultats suggèrent qu'il existe une relation dose-réponse linéaire très significative entre les niveaux circulants de 25-OH-D et la survie globale chez les patients atteints de cancer du sein.
Veuillez lire l'article complet (en anglais seulement) :
Integr Cancer Ther. 2017 May 1:1534735417712007. doi: 10.1177/1534735417712007.
Circulating Vitamin D and Overall Survival in Breast Cancer Patients: A Dose-Response Meta-Analysis of Cohort Studies.Hu K1, Callen DF2, Li J1, Zheng H1.
Studies have shown that vitamin D could have a role in breast cancer survival; however, the evidence of the relationship between patients' vitamin D levels and their survival has been inconsistent. This meta-analysis explores possible dose-response relationships between vitamin D levels and overall survival by allowing for differences in vitamin D levels among populations of the various studies.
Studies relating vitamin D (25-OH-D [25-hydroxyvitamin D]) levels in breast cancer patients with their survival were identified by searching PubMed and Embase. A pooled HR (hazard ratio) comparing the highest with the lowest category of circulating 25-OH-D levels were synthesized using the Mantel-Haenszel method under a fixed-effects model.
A two-stage fixed-effects dose-response model including both linear (a log-linear dose-response regression) and nonlinear (a restricted cubic spline regression) models were used to further explore possible dose-response relationships. Six studies with a total number of 5984 patients were identified.
A pooled HR comparing the highest with the lowest category of circulating 25-OH-D levels under a fixed-effects model was 0.67 (95% confidence interval = 0.56-0.79, P < .001). Utilizing a dose-response meta-analysis, the pooled HR for overall survival in breast cancer patients was 0.994 (per 1 nmol/L), Pfor linear trend < .001.
At or above a 23.3 nmol/L threshold, for a 10 nmol/L, 20 nmol/L, or 25 nmol/L increment in circulating 25-OH-D levels, the risk of breast cancer overall mortality decreased by 6%, 12%, and 14%, respectively.
There was no significant nonlinearity in the relationship between overall survival and circulating 25-OH-D levels.
Our findings suggest that there is a highly significant linear dose-response relationship between circulating 25-OH-D levels and overall survival in patients with breast cancer.
However, better designed prospective cohort studies and clinical trials are needed to further confirm these findings.